195 related articles for article (PubMed ID: 33790652)
1. Radiomics Model Based on Gadoxetic Acid Disodium-Enhanced MR Imaging to Predict Hepatocellular Carcinoma Recurrence After Curative Ablation.
Zhang L; Cai P; Hou J; Luo M; Li Y; Jiang X
Cancer Manag Res; 2021; 13():2785-2796. PubMed ID: 33790652
[TBL] [Abstract][Full Text] [Related]
2. Radiomics-based model using gadoxetic acid disodium-enhanced MR images: associations with recurrence-free survival of patients with hepatocellular carcinoma treated by surgical resection.
Zhang L; Hu J; Hou J; Jiang X; Guo L; Tian L
Abdom Radiol (NY); 2021 Aug; 46(8):3845-3854. PubMed ID: 33733337
[TBL] [Abstract][Full Text] [Related]
3. A radiomics-based model can predict recurrence-free survival of hepatocellular carcinoma after curative ablation.
Peng W; Jiang X; Zhang W; Hu J; Zhang Y; Zhang L
Asian J Surg; 2023 Jul; 46(7):2689-2696. PubMed ID: 36351862
[TBL] [Abstract][Full Text] [Related]
4. Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram.
Yuan C; Wang Z; Gu D; Tian J; Zhao P; Wei J; Yang X; Hao X; Dong D; He N; Sun Y; Gao W; Feng J
Cancer Imaging; 2019 Apr; 19(1):21. PubMed ID: 31027510
[TBL] [Abstract][Full Text] [Related]
5. Delta-radiomics Analysis Based on Multi-phase Contrast-enhanced MRI to Predict Early Recurrence in Hepatocellular Carcinoma After Percutaneous Thermal Ablation.
Huang W; Pan Y; Wang H; Jiang L; Liu Y; Wang S; Dai H; Ye R; Yan C; Li Y
Acad Radiol; 2024 Jun; ():. PubMed ID: 38902111
[TBL] [Abstract][Full Text] [Related]
6. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI.
Wang W; Gu D; Wei J; Ding Y; Yang L; Zhu K; Luo R; Rao SX; Tian J; Zeng M
Eur Radiol; 2020 May; 30(5):3004-3014. PubMed ID: 32002645
[TBL] [Abstract][Full Text] [Related]
7. Radiomics on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for Prediction of Postoperative Early and Late Recurrence of Single Hepatocellular Carcinoma.
Kim S; Shin J; Kim DY; Choi GH; Kim MJ; Choi JY
Clin Cancer Res; 2019 Jul; 25(13):3847-3855. PubMed ID: 30808773
[TBL] [Abstract][Full Text] [Related]
8. A radiomics nomogram for predicting cytokeratin 19-positive hepatocellular carcinoma: a two-center study.
Zhang L; Zhou H; Zhang X; Ding Z; Xu J
Front Oncol; 2023; 13():1174069. PubMed ID: 37182122
[TBL] [Abstract][Full Text] [Related]
9. Radiomics model based on preoperative gadoxetic acid-enhanced MRI for predicting liver failure.
Zhu WS; Shi SY; Yang ZH; Song C; Shen J
World J Gastroenterol; 2020 Mar; 26(11):1208-1220. PubMed ID: 32231424
[TBL] [Abstract][Full Text] [Related]
10. CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation.
Shan QY; Hu HT; Feng ST; Peng ZP; Chen SL; Zhou Q; Li X; Xie XY; Lu MD; Wang W; Kuang M
Cancer Imaging; 2019 Feb; 19(1):11. PubMed ID: 30813956
[TBL] [Abstract][Full Text] [Related]
11. Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm.
Chong HH; Yang L; Sheng RF; Yu YL; Wu DJ; Rao SX; Yang C; Zeng MS
Eur Radiol; 2021 Jul; 31(7):4824-4838. PubMed ID: 33447861
[TBL] [Abstract][Full Text] [Related]
12. Peritumoral Dilation Radiomics of Gadoxetate Disodium-Enhanced MRI Excellently Predicts Early Recurrence of Hepatocellular Carcinoma without Macrovascular Invasion After Hepatectomy.
Chong H; Gong Y; Pan X; Liu A; Chen L; Yang C; Zeng M
J Hepatocell Carcinoma; 2021; 8():545-563. PubMed ID: 34136422
[TBL] [Abstract][Full Text] [Related]
13. A Radiomics Signature-Based Nomogram to Predict the Progression-Free Survival of Patients With Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation.
Fang S; Lai L; Zhu J; Zheng L; Xu Y; Chen W; Wu F; Wu X; Chen M; Weng Q; Ji J; Zhao Z; Tu J
Front Mol Biosci; 2021; 8():662366. PubMed ID: 34532340
[No Abstract] [Full Text] [Related]
14. Spleen Radiomics Signature: A Potential Biomarker for Prediction of Early and Late Recurrences of Hepatocellular Carcinoma After Resection.
Li P; Wu L; Li Z; Li J; Ye W; Shi Z; Xu Z; Zhu C; Ye H; Liu Z; Liang C
Front Oncol; 2021; 11():716849. PubMed ID: 34485152
[TBL] [Abstract][Full Text] [Related]
15. A Radiomics Nomogram for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma.
Yang L; Gu D; Wei J; Yang C; Rao S; Wang W; Chen C; Ding Y; Tian J; Zeng M
Liver Cancer; 2019 Oct; 8(5):373-386. PubMed ID: 31768346
[TBL] [Abstract][Full Text] [Related]
16. Radiomics analysis of ultrasound to predict recurrence of hepatocellular carcinoma after microwave ablation.
Wu JP; Ding WZ; Wang YL; Liu S; Zhang XQ; Yang Q; Cai WJ; Yu XL; Liu FY; Kong D; Zhong H; Yu J; Liang P
Int J Hyperthermia; 2022; 39(1):595-604. PubMed ID: 35435082
[TBL] [Abstract][Full Text] [Related]
17. Radiomic Features at Contrast-enhanced CT Predict Recurrence in Early Stage Hepatocellular Carcinoma: A Multi-Institutional Study.
Ji GW; Zhu FP; Xu Q; Wang K; Wu MY; Tang WW; Li XC; Wang XH
Radiology; 2020 Mar; 294(3):568-579. PubMed ID: 31934830
[TBL] [Abstract][Full Text] [Related]
18. Gadoxetic acid-enhanced MRI radiomics signature: prediction of clinical outcome in hepatocellular carcinoma after surgical resection.
Zhang Z; Chen J; Jiang H; Wei Y; Zhang X; Cao L; Duan T; Ye Z; Yao S; Pan X; Song B
Ann Transl Med; 2020 Jul; 8(14):870. PubMed ID: 32793714
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Locoregional Recurrence-Free Survival of Oesophageal Squamous Cell Carcinoma After Chemoradiotherapy Based on an Enhanced CT-Based Radiomics Model.
Kong J; Zhu S; Shi G; Liu Z; Zhang J; Ren J
Front Oncol; 2021; 11():739933. PubMed ID: 34631575
[TBL] [Abstract][Full Text] [Related]
20. Development and External Validation of a Radiomics Model Derived from Preoperative Gadoxetic Acid-Enhanced MRI for Predicting Histopathologic Grade of Hepatocellular Carcinoma.
Hu X; Li C; Wang Q; Wu X; Chen Z; Xia F; Cai P; Zhang L; Fan Y; Ma K
Diagnostics (Basel); 2023 Jan; 13(3):. PubMed ID: 36766518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
